ArticleInvestigative ophthalmology & visual science2025
Establishment of an Advanced In Vitro Model for Pseudoexfoliation Syndrome and Glaucoma.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Pseudoexfoliation (PEX) glaucoma is caused by progressive accumulation of abnormal fibrillar aggregates in aqueous humor outflow tissues. The current lack of effective models for PEX research, replicating the key feature of PEX material production, represents a critical gap in understanding the molecular pathomechanisms and identifying specific therapeutic targets. We have developed an advanced in vitro model using stromal fibroblasts from iridectomy specimens of PEX glaucoma patients with an appropriate genetic background. Methods: Peripheral iridectomy specimens were obtained from patients with PEX glaucoma (n = 35) during routine trabeculectomy. Stromal fibroblasts were enriched from heterogenous cell cultures. Extracellular matrix formation was stimulated and modulated in two- and three-dimensional (3D) spheroid cultures by TGF-β1, Ficoll 400, all-trans-retinoic acid (ATRA), and curcumin. Cell cultures were analyzed by immunocytochemistry, transmission electron microscopy and qPCR. Immortalized cell lines (n = 4) were generated by SV40 large T-antigen transfection. Results: Fibroblasts carrying the high-risk haplotype of LOXL1 (lysyl oxidase-like 1) expressed PEX-relevant matrix components and assembled an elastic fibrillar network, particularly upon treatment with TGF-β1 and the macromolecular crowding agent Ficoll 400. In 3D spheroid cultures, the presence of typical fibrillar PEX aggregates could be demonstrated by electron microscopy. Matrix production could be effectively suppressed by ATRA and curcumin. Similar to primary cells, immortalized cell lines formed 3D spheroids and expressed PEX-relevant matrix components including typical fibrillar aggregates. Conclusions: This advanced in vitro model, which recapitulates the hallmark of PEX syndrome/glaucoma, may provide a useful, easy-to-handle platform for studying disease mechanisms, assessing the impact of genetic and external factors, and exploring effects of targeted therapies for PEX-associated fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.